PP1 peptide
PP1 peptide is an antagonist that specifically binds to scavenger receptor AI (SR-AI), with an IC50 of 29 μM against bovine SR-AI. By recognizing SR-AI which is highly expressed on macrophages, PP1 peptide enables precise targeting and internalization of inflammatory regions within atherosclerotic plaques. PP1 peptide can be used in research related to atherosclerosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 870274-84-3
- Fòrmula: C79H122N22O22S
- Peso molecular:1764.01
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
PP1 peptide (0-300 μM) potently inhibits the binding of SR-AI-targeting phages to immobilized recombinant SR-AI, with an IC50 of 29 μM, and its N-terminal region is critical for activity[1].
The PP1 peptide binds to mouse RAW264.7 macrophages in an SR-AI-dependent manner, as demonstrated by fucoidan-mediated inhibition assays, with an IC50 of 4.2 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PP1 (0.38 μM; intravenous injection; single administration) selectively targets advanced atherosclerotic plaques in ApoE-/- mice, increases the maximum carrier accumulation by 93.7%, colocalizes with 52.4% of macrophages in plaques, and does not alter plaque size[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ApoE-/- (male, ~65 weeks old, back-crossed for 9 generations on a C57Bl/6 background)[1]
-
Dosage:0.38 μM
-
Administration:i.v.; single dose
-
Result:Showed an 84.12% increase in aortic plaque accumulation compared with untargeted 125I-streptavidin, with no difference in plaque size between groups.
Showed a 93.65% increase in aortic plaque accumulation compared with untargeted Quantumdot Nanocrystals.
Colocalized with 52.4% of intraplaque F4/80-positive macrophages, compared with 6.3% for untargeted Quantumdots.
Chemical Information
-
No. CAS 870274-84-3
-
Peso molecular 1764.01
-
Fòrmula C79H122N22O22S
-
SMILES
O=C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CS)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N4[C@@H](CCC4)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N
-
Sequence
Leu-Ser-Leu-Glu-Arg-Phe-Leu-Arg-Cys-Trp-Ser-Asp-Ala-Pro-Ala
-
Sequence Shortening
LSLERFLRCWSDAPA
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PP1 peptide Related Classifications
HY-P12012 Related Classifications
Powered by Bioz